Moderna (MRNA) Enterprise Value (2017 - 2026)
Moderna (MRNA) posted quarterly Enterprise Value of -$5.1 billion for Q2 2026, little changed year-over-year from -$5.1 billion in Q2 2025, and up 1.29% on a QoQ basis from -$5.2 billion in Q1 2026.
Moderna (MRNA) Enterprise Value (2017 - 2026) Analysis & Trends
Moderna has reported Enterprise Value for 10 years, with the latest figure at -$5.1 billion in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$5.1 billion, changed 0.14% year-over-year; the trailing twelve-month figure through Jun 2026 was -$5.1 billion (changed 0.14% YoY), and the FY2025 annual result was -$5.8 billion, up 17.45% from the prior year.
- Enterprise Value rose to -$5.1 billion in Q2 2026, from -$5.2 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$4.5 billion in Q3 2025 and troughed at -$10.1 billion in Q1 2022.
- A 5-year average of -$7.4 billion and a median of -$7.7 billion in 2022 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2022, when Enterprise Value sank 30.77%; it then soared 39.55% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$9.9 billion in 2022, then advanced by 13.11% to -$8.6 billion in 2023, then advanced by 18.35% to -$7.0 billion in 2024, then climbed by 17.45% to -$5.8 billion in 2025, then grew by 11.4% to -$5.1 billion in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$5.1 billion in Q2 2026, -$5.2 billion in Q1 2026, and -$5.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Roivant Sciences | 26.52 Bn | 26.52 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.14 Bn |
| Mar 31, 2026 | -5.21 Bn |
| Dec 31, 2025 | -5.80 Bn |
| Sep 30, 2025 | -4.50 Bn |
| Jun 30, 2025 | -5.13 Bn |
| Mar 31, 2025 | -5.98 Bn |
| Dec 31, 2024 | -7.03 Bn |
| Sep 30, 2024 | -6.87 Bn |
| Jun 30, 2024 | -8.49 Bn |
| Mar 31, 2024 | -8.52 Bn |
| Dec 31, 2023 | -8.60 Bn |
| Sep 30, 2023 | -7.57 Bn |
| Jun 30, 2023 | -8.46 Bn |
| Mar 31, 2023 | -8.92 Bn |
| Dec 31, 2022 | -9.90 Bn |
| Sep 30, 2022 | -8.35 Bn |
| Jun 30, 2022 | -7.90 Bn |
| Mar 31, 2022 | -10.12 Bn |
| Dec 31, 2021 | -10.73 Bn |
| Sep 30, 2021 | -8.91 Bn |